Search

  • HOME
  • Search
Editorial
1590
Metabolic disease as a risk of hepatocellular carcinoma
Naoshi Nishida
Clin Mol Hepatol. 2021;27(1):87-90.   Published online December 3, 2020
View: 5196   Download: 114  Web of Science: 12  Crossref: 14
Long-term prognosis and management of hepatocellular carcinoma after curative treatment
Naoshi Nishida
Clin Mol Hepatol. 2020;26(4):480-483.   Published online September 21, 2020
View: 5538   Download: 101  Web of Science: 12  Crossref: 11
Atezolizumab and bevacizumab for hepatocellular carcinoma: how to approach salvage therapy for non-responders?
Naoshi Nishida
Received May 2, 2024  Accepted May 3, 2024  
View: 520   Download: 57
Personalized Approaches to the Treatment of Hepatocellular Carcinoma Using Immune Checkpoint Inhibitors
Naoshi Nishida
Received September 1, 2024  Accepted September 3, 2024  
View: 210   Download: 20  Crossref: 1
1 |

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X


Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: kasl@kams.or.kr
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 619
TOTAL : 2102218
Close layer